Skip to Main content Skip to Navigation
Journal articles

Peptidomimetic-based identification of FDA approved compounds inhibiting IRE1 activity

Abstract : Inositol Requiring Enzyme 1 (IRE1) is a bifunctional serine/threonine kinase and endoribonuclease that is a major mediator of the Unfolded Protein Response (UPR) during endoplasmic reticulum (ER) stress. Tumour cells experience ER stress due to adverse environmental cues such as hypoxia or nutrient shortage and high metabolic/protein folding demand. To cope with those stresses, cancer cells utilise IRE1 signalling as an adaptive mechanism. Here we report the discovery of the FDA approved compounds methotrexate, cefoperazone, folinic acid and fludarabine phosphate as IRE1 inhibitors. These were identified through a structural exploration of the IRE1 kinase domain using IRE1 peptide fragment docking and further optimization and pharmacophore development. The inhibitors were verified to have an impact on IRE1 activity in vitro and were tested for their ability to sensitise human cell models of glioblastoma multiforme (GBM) to chemotherapy. We show that all molecules identified sensitise glioblastoma cells to the standard of care chemotherapy temozolomide (TMZ).
Document type :
Journal articles
Complete list of metadata
Contributor : Laurent Jonchère Connect in order to contact the contributor
Submitted on : Tuesday, June 9, 2020 - 1:43:49 PM
Last modification on : Tuesday, February 2, 2021 - 10:53:26 AM

Links full text



Dimitrios Doultsinos, Antonio Carlesso, Chetan Chintha, James C Paton, Adrienne W Paton, et al.. Peptidomimetic-based identification of FDA approved compounds inhibiting IRE1 activity. FEBS Journal, Wiley, 2021, 288 (3), pp.945-960. ⟨10.1111/febs.15372⟩. ⟨hal-02862262⟩



Record views